New evidence has linked physical activity with improved colon health, underscoring the vital role of exercise in cancer ...

The global immuno-oncology market is set to witness a growth rate of 21% in the next 5 years. Increasing incidence and ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Stage 0 cancers seldom cause symptoms or lumps and are typically detected through screening, namely a mammogram. The breast ...

Despite having no symptoms, Linda’s commitment to preventive care led to a life-saving lung cancer diagnosis. Learn why early ...

Lung cancer patients can expect improved long term survival under a new treatment combination, according to new Irish research published today. The patients with lung cancer who received an ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

CHICAGO -- The bispecific T-cell engager tarlatamab (Imdelltra) significantly prolonged survival in the second-line treatment ...

Imdelltra improved survival and quality of life versus chemotherapy as second-line treatment for small cell lung cancer, ...

The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

After years of lobbying from patients, the first ever national lung cancer screening program will roll out next month for ...